Stockscreener 앱 받기
13.00
1.33%
0.17
Viatris Inc 주식(VTRS)의 최신 뉴스
Cerebral Palsy Treatment Market Growth Overview: - openPR
Transdermal Skin Patches Market Overall Study Report 2024-2031 - openPR
Safecor Health Acquires Viatris’ U.S. Unit-Dose Packaging Business - citybiz
Safecor Health Announces Acquisition of Viatris' U.S. Unit-Dose Packaging Business - Kilgore News Herald
VSCP-backed Safecor Health picks up Viatris Inc’s US unit-dose packaging business - PE Hub
Influenza Vaccines Industry May See a Big Move | BIKEN, Viatris, Sinovac Biotech - openPR
Chris Davis's Strategic Acquisition of Viatris Inc Shares - GuruFocus.com
Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles - Investing.com
Viatris Inc's chief accounting officer sells $346,686 in stock - Investing.com India
Viatris Inc's chief accounting officer sells $346,686 in stock By Investing.com - Investing.com Australia
YieldBoost VTRS To 8.9% Using Options - Nasdaq
Bargain Priced Viatris Reports Strong Q3 Earnings Results (NASDAQ:VTRS) - Seeking Alpha
Viatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Call Transcript - MSN
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus.com
Viatris: Q3 Earnings Snapshot - AOL
Viatris reports 71% decline in Q3 2024 net income to $95m - World Pharmaceutical Frontiers
Earnings call: Viatris reports robust Q3 with revenue growth and debt reduction - Investing.com India
Viatris Inc. Reports Strong Q3 2024 Performance - TipRanks
Viatris Outshines Wall Street With Unexpected Profit Gains - Finimize
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance - MSN
Viatris Reports Third Quarter Financial Results for 2024 - citybiz
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown - Benzinga
Viatris Inc (VTRS) Q3 2024 Earnings: Revenue Hits $3.8 Billion, EPS Falls Short at $0.08 - GuruFocus.com
Viatris stock jumps after Q3 beat (VTRS:NASDAQ) - Seeking Alpha
Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xanax maker Viatris beats quarterly estimates on demand for new generic drugs - Reuters
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Viatris Q3 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Viatris Inc. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Viatris to Report Q3 Earnings: What's in the Cards? - MSN
Viatris Q3 Earnings Preview: Focus on upcoming product launches and EBITDA growth - Seeking Alpha
Are Wall Street Analysts Predicting Viatris Stock Will Climb Or Sink? - Barchart
Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink? - MSN
Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type - GlobeNewswire Inc.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings? - Yahoo Finance
Viatris Announces Third Quarter 2024 Dividend - BioSpace
Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021 - BioSpace
Where are the Opportunities in (VTRS) - Stock Traders Daily
Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Covestro, American Eagle, Howmet and Viatris all make Forbes list of Top Companies for Women - The Business Journals
Viatris Named to Forbes' World's Top Companies for Women 2024 List - Quantisnow
0.37%
0.54%
자본화:
|
볼륨(24시간):